← Back to graph
Prescription

adalimumab psoriasis

Selected indexed studies

  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. (J Am Acad Dermatol, 2017) [PMID:28057360]
  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. (J Am Acad Dermatol, 2017) [PMID:28057361]
  • Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis. (JAMA Dermatol, 2025) [PMID:40465280]

_Worker-drafted node — pending editorial review._

Connections

No connections recorded yet.

Sources

Local graph